Our third program, APG990, has been engineered to bind to OX40L, blocking interactions with OX40 and rebalancing cellular immune responses in AD. OX40L and its receptor, OX40, are important regulators of cellular immune responses. Imbalances in the OX40L and OX40 system and, thus, imbalances between pro-inflammatory and anti-inflammatory T cells, have been implicated in the pathogenesis of AD. Inhibiting the OX40-OX40L pathway could represent another therapeutic option for people living with AD, especially for those who do not benefit from currently available treatments. APG990 has also been designed to bind to FcRn with high affinity, extending biologic circulation times potentially requiring less frequent dosing.
Next Anticipated Milestones